MADISON HEIGHTS, Mich., May 21, 2012 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE MKT: INFU) ("InfuSystem" or the "Company"), the leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported results for the first quarter ended March 31, 2012.
Revenues for the quarter ending March 31, 2012 were $14.3 million, up 11% from $13.0 million in the first quarter of 2011. Gross profit for the three months ending March 31, 2012 was $10.4 million, up 15% from $9.1 million in first quarter of last year. First quarter net loss was $0.9 million, equal to $0.04 loss per diluted share, compared to $0.2 million net loss, equal to $0.01 income per diluted share in the prior period.
Ryan Morris, the newly appointed Executive Chairman, said the first quarter results provide a solid foundation for the new management team that took office in late April, and whose strategy for achieving growth and increasing shareholder value should begin to be reflected in subsequent quarterly results. Since mid-March, the Company has welcomed the arrival of Interim Chief Executive Officer Dilip Singh, Chief Financial Officer Jonathan P. Foster, as well as five new Board members.
"It's been a very eventful quarter for the Company and I am proud that our employees and operational management continued the top line revenue growth while these Board and management changes took place," Morris said.
The new management team has already begun building on those efforts, starting first with a series of operational improvements, integration of past acquisitions to generate new synergies for the Company and cost-savings initiatives – some of which will be announced soon and some of which are already underway.
Interim Chief Executive Officer Dilip Singh said these operational improvements are just the first steps the Company will implement as part of a broader strategy to achieve long-term growth. "Our initial focus is to maximize cash generation with EBITDA for sustained financial stability while achieving growth by continuing to take market share in our core markets. Over the long-term, we see significant, recurring opportunity for organic growth, notably by enhancing customer service solutions that make it easier for our various partners, channels and customers to rent, lease or buy new and reconditioned pumps with just in time inventory; entering other vertical medical markets disciplines; and, in time, expanding our franchise model globally."
Operating Results The 11% increase in revenues relative to the first quarter of 2011 is primarily related to the addition of new customers with larger patient bases, increased penetration into our existing customer accounts and the resolution of the oncology drug shortage affecting certain products.
The $10.4 million in gross profit recorded in the first quarter of 2012 represented 73% of revenues for the current period compared with 70% percent in the prior year's period. The increase in the gross margin percentage was primarily related to lower pump depreciation and a higher mix of third party billings as compared to pump sales, rentals and services.
Selling, general and administrative expenses (SG&A) for the first quarter of fiscal 2012 were $10.9 million, 24 percent higher than the prior period's $8.8 million. As a percent of revenues, SG&A was 76 percent compared to 62 percent for the prior fiscal year (excluding non-cash impairment charges). The major factors contributing to the increase of $2.1 million in SG&A were expenses of $1.5 million related primarily to legal fees and other costs associated with activities related to negotiating and entering into a settlement agreement with a concerned stockholder group and a fifth amendment to the Company's credit facility. The settlement agreement and fifth amendment to the credit facility are described in the 8-K the Company filed on April 26th. Additional related fees and expenses are expected in the second quarter of 2012.
EBITDA for the first quarter of fiscal 2012 was $1.6 million compared to $2.4 million a year ago. Excluding the one-time fees associated with the activities described above, EBITDA would have been $3.1 million. A Non-GAAP reconciliation from net income can be found in the appendix.
Financial ConditionNet cash provided by operations for the first quarter ending March 31, 2012 was $0.1 million, compared to $2.1 million in the prior period. The latest quarter's results reflected increased professional fees associated with the concerned stockholder group and employee compensation costs. In addition, the Company reported capital expenditures of $1.2 million, a decrease of $1.2 million compared to the prior period. The cash balance decreased by $3.2 million from the comparable period in the prior year due to issues noted herein and the Company ended the quarter with no cash on the balance sheet due to outstanding payments. The Company had $2.5 million drawn as of March 31, 2012, on its $5.0 million revolving credit facility.
During the quarter, the Company continued to make the required payments on its $21.0 million in long-term debt.
Conference CallThe Company will host a conference call to share the results of its first quarter fiscal 2012 results on Tuesday, May 22, at 9:00 a.m. Eastern Time. Dilip Singh, Interim Chief Executive Officer, and Jonathan P. Foster, Chief Financial Officer, will discuss the Company's financial performance and answer questions from the financial community.
The Company invites interested investors to listen to the presentation, which will be carried live on the Company's Web site: www.infusystem.com in the Investors section. To participate by telephone, the dial-in number is (888)-895-5271 with confirmation number 32474314. Those who wish to listen should either dial in or go to the web site several minutes prior to the call to register. An online archive of the conference call will remain on the Company's Web site for the following 30 days.
About InfuSystem Holdings, Inc. InfuSystem Holdings, Inc. is the leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada. The Company's stock is traded on the NYSE MKT under the symbol INFU.
Forward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks, detailed from time to time in the Company's publicly filed documents.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.INVESTOR CONTACT:
Jonathan P. Foster
Chief Financial OfficerInfo@InfuSystem.com
800-962-9656FINANCIAL TABLES FOLLOWINFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(UNAUDITED)March 31,December 31,(in thousands, except share data)20122011ASSETSCurrent Assets:
Cash and cash equivalents
Accounts receivable, less allowance for doubtful accounts of $2,021 and
$1,773 at March 31, 2012 and December 31, 2011, respectively
Accounts receivable - related party
Prepaid expenses and other current assets
Deferred income taxes
Total Current Assets
13,080Property & equipment, net
15,764Deferred debt issuance costs, net
421Intangible assets, net
28,221Deferred income taxes
76,263LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:
Accounts payable - related party
Other current liabilities
Current portion of long-term debt
Total Current Liabilities
13,132Revolving credit facility
-Long-term debt, net of current portion
36,098Stockholders' Equity:Common stock, $.0001 par value; authorized 200,000,000 shares; issued 21,330,235 and 21,330,235, respectively; outstanding 21,132,545 and 21,132,545, respectively2
2Additional paid-in capital
87,541Accumulated other comprehensive loss
(47,242)Total Stockholders' Equity
Total Liabilities and Stockholders' Equity
76,263INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)(in thousands, except share data)20122011Net revenuesRentals
12,957Cost of revenues:
Cost of revenues — Product, service and supply costs
Cost of revenues — Pump depreciation, sales and disposals
1,761 Gross profit
9,053Selling, general and administrative expenses:
Provision for doubtful accounts
Amortization of intangibles
Asset impairment charges
Selling and marketing
General and administrative
Total sales, general and administrative
8,826Operating (loss) income
227Other income (expense):
Other income (expense)
Total other loss
(544)Loss before income taxes
(317)Income tax benefit
(171)Net loss per share:
Basic and diluted
(0.01)Weighted average shares outstanding:
Basic and diluted
21,012,312Comprehensive LossNet loss
(171)Unrealized gain on interest rate swap, net of taxes
(124)INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)Three Months EndedMarch 31(in thousands)20122011OPERATING ACTIVITIESNet loss
$ (171)Adjustments to reconcile net loss to net cash provided by
Provision for doubtful accounts
Loss on disposal of pumps
Amortization of intangible assets
Amortization of deferred debt issuance costs
Deferred income taxes
(146)Changes in Assets - (Increase)/Decrease:
Accounts receivable, net of provision
Other current assets
(11)Changes in Liabilities - Increase/(Decrease), exclusive of effects of acquisitions:
Accounts payable and other liabilities
(152)NET CASH PROVIDED BY OPERATING ACTIVITIES
Acquisition of intangible assets
-NET CASH USED IN INVESTING ACTIVITIES
Principal payments on term loan and seller's note
(1,030)Proceeds from draw on revolving credit facility
Treasury shares repurchased
Principal payments on capital lease obligations
(263)NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
(1,522)Net change in cash and cash equivalents
(1,838)Cash and cash equivalents, beginning of period
5,014Cash and cash equivalents, end of period
$ 3,176INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIESNON-GAAP RECONCILIATION(UNAUDITED)Three Months EndedMarch 31 (unaudited)(in thousands, except share data)20122011Net loss
(171)Adjustments: Interest expense
601541 Income tax benefit
|SOURCE InfuSystem Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved